The Impact of Obesity on Radiotherapy Anti-Tumor Effects

肥胖对放射治疗抗肿瘤效果的影响

• 批准号: 10367904
• 负责人: Arta Monir Monjazeb
• 金额: $ 53.25万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10367904
• 关键词: Address; Adoptive Transfer; Affect; Apoptotic; BCL2 gene; Biological; Cancer Model; Cancer Patient; Cell Proliferation; Clinical; Clinical Data; Clinical Research; Data; Dose; Effectiveness; Functional disorder; Genes; Hormonal Change; Hormones; Immune; Immune System Diseases; Immune response; Immune system; Implant; In Vitro; Inflammation; Knowledge; Lead; Leptin; Link; Malignant Neoplasms; Mediating; Metabolic; Modeling; Mus; Obese Mice; Obesity; Outcome; Patients; Phenotype; Preventable cancer cause; Production; Publishing; Radiation Physics; Radiation therapy; Recurrence; Regulation; Resistance; Signal Transduction; Smoking; T-Lymphocyte; Testing; Thinness; Toxic effect; Tumor Biology; Tumor Immunity; United States; Up-Regulation; adipokines; antitumor effect; base; cancer cell; cancer recurrence; cancer survival; cancer therapy; diet-induced obesity; exhaustion; immunosuppressed; improved; improved outcome; in vivo; mouse model; obese patients; pandemic disease; personalized medicine; pre-clinical; preclinical study; radiation delivery; radiation resistance; radiation response; response; survivin; treatment strategy; tumor; tumor growth; tumor metabolism; tumor microenvironment

Abstract Obesity has reached pandemic levels in the United States and will soon surpass smoking as the number one cause of preventable cancer. Understanding how to best treat obese cancer patients is a critical unmet need. Preclinical data from our lab show increased resistance to radiotherapy (RT) in obese mouse cancer models. Clinical data demonstrates that obese cancer patients are more resistant to radiotherapy and have higher rates of recurrence. Very few mechanistic studies have addressed these findings and understanding the mechanisms governing radiotherapy resistance in obesity is a gap in knowledge. Our prior studies demonstrate that obesity, likely via leptin, a hormone elevated in obesity, can alter the proliferation / survival of cancers and also change the immune response to cancer, leading to changes in the efficacy of cancer therapies. Obesity suppresses adaptive T cell anti-tumor immunity and the immune system strongly contributes to the anti-tumor effects of RT, providing a potential mechanism linking obesity and RT resistance. Obesity related adipokines can induce anti- apoptotic factors and RT resistance. Based on these observations we hypothesize that obesity induces resistance to RT directly by increasing anti-apoptotic factors in cancer cells and indirectly by inducing suppression of adaptive anti-tumor immunity in the tumor microenvironment (TME). We also hypothesize that leptin signaling may mediate the RT resistance observed in obesity. This proposal seeks to test these hypotheses and further delineate mechanistic links between obesity and RT resistance using three specific aims. We will use lean and diet induced obesity (DIO) mouse models, immunosuppressed mice (Rag2 -/-), as well as mice that lack functional leptin signaling (db/db) or lack endogenous leptin (ob/ob) to evaluate how obesity and leptin signaling within cancer cells and within the tumor microenvironment influence resistance to radiotherapy. In specific aim 1 we will examine the effects of obesity on the efficacy of RT and also examine the direct effects on the tumor as well as the indirect effects via T cell dysfunction or other immune mechanisms. In specific aim 2 we will investigate leptin signaling as an underlying mechanism whereby obesity induces resistance to RT both through direct effects on cancer cell proliferation / survival and also through indirect effects on the TME. In specific aim 3 we will test an exploratory hypothesis that ablative RT is able to improve RT efficacy in obesity by overcoming the mechanisms of obesity induced direct (but not immune related indirect) RT resistance. Understanding how obesity impacts RT response and developing strategies to address these issues will improve outcomes in obese patients treated with RT. Thus, these studies can have a major clinical impact and represent a step towards personalized medicine by tailoring RT treatment strategies to a patient's metabolic parameters.

摘要 肥胖症在美国已经达到了流行病的程度，很快就会超过吸烟成为头号杀手 可预防的癌症的原因。了解如何最好地治疗肥胖癌症患者是一个关键的未满足的需求。 我们实验室的临床前数据显示，肥胖小鼠癌症模型对放疗（RT）的抵抗力增加。 临床数据表明，肥胖的癌症患者对放射治疗更有抵抗力， 的复发。很少有机制研究已经解决了这些发现和理解的机制 在肥胖症中控制放射治疗抵抗是一个知识空白。我们之前的研究表明肥胖， 可能通过瘦素，一种在肥胖症中升高的激素，可以改变癌症的增殖/存活， 对癌症的免疫反应，导致癌症治疗效果的变化。肥胖抑制 适应性T细胞抗肿瘤免疫和免疫系统对RT的抗肿瘤作用有很大贡献， 提供了一种将肥胖和RT抗性联系起来的潜在机制。肥胖相关脂肪因子可诱导抗- 凋亡因子和RT抵抗。基于这些观察，我们假设肥胖诱导 直接通过增加癌细胞中的抗凋亡因子和间接通过诱导 抑制肿瘤微环境（TME）中的适应性抗肿瘤免疫。我们还假设 瘦素信号可能介导肥胖中观察到的RT抗性。这项建议旨在测试这些 假设和进一步描绘肥胖和RT抵抗之间的机械联系，使用三个具体的目标。 我们将使用瘦型和饮食诱导的肥胖（DIO）小鼠模型、免疫抑制小鼠（Rag 2-/-），以及 缺乏功能性瘦素信号传导（db/db）或缺乏内源性瘦素（ob/ob）的小鼠，以评估肥胖和 癌细胞内和肿瘤微环境内的瘦素信号传导影响对放射疗法的抗性。 在具体目标1中，我们将检查肥胖对RT疗效的影响，并检查直接影响 以及通过T细胞功能障碍或其他免疫机制的间接作用。具体目标 我们将研究瘦素信号传导作为肥胖诱导RT抵抗的潜在机制， 通过对癌细胞增殖/存活的直接影响以及通过对TME的间接影响。在 具体目标3：我们将检验一个探索性假设，即消融性RT能够通过以下方式改善肥胖患者的RT疗效： 克服肥胖诱导的直接（而非免疫相关的间接）RT抗性的机制。 了解肥胖如何影响RT反应，并制定解决这些问题的策略， 因此，这些研究可能具有重大临床影响 并通过根据患者的代谢情况定制RT治疗策略， 参数